The Therapeutic Goods Administration regulates medicinal cannabis within the broader framework of therapeutic goods in Australia. Its role is not to promote or prescribe products, but to oversee how they are classified, supplied, and controlled.
Medicinal cannabis products are often described as “unapproved therapeutic goods”. This does not mean they are unregulated. Instead, it reflects the fact that they are accessed through specific pathways rather than being included on the Australian Register of Therapeutic Goods for general supply.
The TGA sets requirements around areas such as:
-
Product classification
-
Quality and manufacturing standards
-
Importation and supply controls
-
Advertising restrictions
These requirements shape how medicinal cannabis is handled at every stage, from production through to patient access.
One of the most important aspects of TGA regulation is its approach to advertising. Australian law restricts how therapeutic goods can be promoted to the public, which is why information about medicinal cannabis is often presented in a factual and limited way.
Understanding the TGA’s role helps clarify why medicinal cannabis is treated differently from many other products. It exists within a system that emphasises regulation and control rather than open promotion.
